Skip to main content
SpringerLink
Log in

Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values?

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

New criteria that define acromegaly remission are more stringent: normal (age/sex-adjusted) insulin-like growth factor type 1 (IGF-1), growth hormone (GH) random (GHr) <1 μg/L, and a GH nadir (GHn) during oral glucose tolerance test (OGTT) of <0.4 μg/L. Discordance between GH and IGF-1 values is often attributed to somatostatin receptor ligands (SRLs) or radiation. The purpose of this study was to evaluate rates of discordant IGF-1 and GH levels in patients with GH secreting adenomas (after pituitary surgery), who were naïve to any other treatment. We retrospectively analyzed data over a 5 year time period (2006–2010), in post-surgery acromegaly patients who had elevated IGF-1 but normal GH levels (per the new cure criteria). Symptoms of acromegaly were scored according to a 4-point scale. Fifty-four patients had post-operative GHr and IGF-1 measurements, 28 patients had GHn during OGTT, and 16 patients had 5-point 2-h GH day curve tests. Thirteen of 54 (24%) patients were found to have intermittent persistent discordant values; high IGF-1 and normal GH at final evaluation (77% of these patients were women). Patients had a median number of IGF-1 evaluations of 7.5 (range: 2–15) over a median of 22 months (range: 3–47 months). Mean elevated IGF-1 in the discordant population was 1.25 × upper limit of normal (ULN) ± 0.17 (range: 1.01–1.6 × ULN). Twelve of the 13 (92%) patients had macroadenomas; 10 of the 13 (69%) patients had mammosomatotroph, mixed lacto/somatotroph tumors or prolactin staining. No patient in the discordant population was on estrogen replacement therapy or had overt cardiac disease. When the relatively asymptomatic discordant population was compared with 35 patients from the concordant population (six were excluded because of preoperative medical treatment for acromegaly), no significant difference between age, gender distribution, body mass index (BMI), presence of diabetes mellitus (DM) or glucose intolerance and adrenal insufficiency between groups was noted. In our study of postoperative patients with acromegaly naïve to both SRLs and radiation, using new GH cut-off levels, 24% had intermittent or persistent discordant values. Our results highlight that relying on IGF-1 or GH measurements alone is not adequate for assessing disease control in surgically treated acromegaly patients. Management of such patients needs to be individualized and long-term studies evaluating morbidity and mortality incorporated into treatment decisions. Further studies with larger patient populations and longer follow-up are required to determine the long-term implications of discordant GH and IGF-1 value patterns.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Holdaway IM, Rajasoorya C (1999) Epidemiology of acromegaly. Pituitary 2(1):29–41

    Article  PubMed  CAS  Google Scholar 

  2. Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72(3):377–382

    Article  Google Scholar 

  3. Rosario PW, Calsolari MR (2011) Screening for acromegaly by application of a simple questionnaire evaluating the enlargement of extremities in adult patients seen at primary health care units. Pituitary. doi:10.1007/s11102-011-0302-7

  4. Schneider HJ, Sievers C, Saller B, Wittchen HU, Stalla GK (2008) High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin Endocrinol (Oxf) 69(3):432–435

    Article  CAS  Google Scholar 

  5. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91(12):4769–4775

    Article  PubMed  CAS  Google Scholar 

  6. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95(7):3141–3148

    Article  PubMed  CAS  Google Scholar 

  7. Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355(24):2558–2573

    Article  PubMed  CAS  Google Scholar 

  8. Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119(11):3189–3202

    Article  PubMed  CAS  Google Scholar 

  9. Sughrue ME, Chang EF, Gabriel RA, Aghi MK, Blevins LS (2011) Excess mortality for patients with residual disease following resection of pituitary adenomas. Pituitary 14(3):276–283

    Article  PubMed  Google Scholar 

  10. Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89(2):667–674

    Article  PubMed  CAS  Google Scholar 

  11. Sherlock M, Reulen RC, Alonso AA, Ayuk J, Clayton RN, Sheppard MC, Hawkins MM, Bates AS, Stewart PM (2009) ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab 94(11):4216–4223

    Article  PubMed  CAS  Google Scholar 

  12. Fleseriu M, Delashaw JB Jr, Cook DM (2010) Acromegaly: a review of current medical therapy and new drugs on the horizon. Neurosurg Focus 29(4):E15

    Article  PubMed  Google Scholar 

  13. Cook DM, Ezzat S, Katznelson L, Kleinberg DL, Laws ER Jr, Nippoldt TB, Swearingen B, Vance ML (2004) AACE medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocr Pract 10(3):213–225

    PubMed  Google Scholar 

  14. Alexopoulou O, Bex M, Abs R, T’Sjoen G, Velkeniers B, Maiter D (2008) Divergence between growth hormone and insulin-like growth factor-I concentrations in the follow-up of acromegaly. J Clin Endocrinol Metab 93(4):1324–1330

    Article  PubMed  CAS  Google Scholar 

  15. Elias PC, Lugao HB, Pereira MC, Machado HR, Castro M, Moreira AC (2010) Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity. Horm Metab Res 42(1):50–55

    Article  PubMed  CAS  Google Scholar 

  16. Machado EO, Taboada GF, Neto LV, van Haute FR, Correa LL, Balarini GA, Shrank Y, Goulart M, Gadelha MR (2008) Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. Growth Horm IGF Res 18(5):389–393

    Article  PubMed  CAS  Google Scholar 

  17. Freda PU, Wardlaw SL, Post KD (1998) Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 89(3):353–358

    Article  PubMed  CAS  Google Scholar 

  18. Jane JA Jr, Starke RM, Elzoghby MA, Reames DL, Payne SC, Thorner MO, Marshall JC, Laws ER Jr, Vance ML (2011) Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. J Clin Endocrinol Metab 96(9):2732–2740

    Article  PubMed  CAS  Google Scholar 

  19. Wu TE, Lin HD, Lu RA, Wang ML, Chen RL, Chen HS (2010) The role of insulin-like growth factor-1 and growth hormone in the mortality of patients with acromegaly after trans-sphenoidal surgery. Growth Horm IGF Res 20(6):411–415

    Article  PubMed  Google Scholar 

  20. Kauppinen-Mäkelin R, Sane T, Reunanen A, Välimäki MJ, Niskanen L, Markkanen H, Löyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman U-H, Viikari J, Voutilainen E (2005) A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 90(7):4081–4086

    Article  PubMed  Google Scholar 

  21. Karavitaki N, Fernandez A, Fazal-Sanderson V, Wass JA (2009) The value of the oral glucose tolerance test, random serum growth hormone and mean growth hormone levels in assessing the postoperative outcome of patients with acromegaly. Clin Endocrinol (Oxf) 71(6):840–845

    Article  CAS  Google Scholar 

  22. Sherlock M, Aragon Alonso A, Reulen RC, Ayuk J, Clayton RN, Holder G, Sheppard MC, Bates A, Stewart PM (2009) Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly. Clin Endocrinol (Oxf) 71(1):74–81

    Article  CAS  Google Scholar 

  23. Clemmons DR (2011) Clinical laboratory indices in the treatment of acromegaly. Clin Chim Acta; Int J Clin Chem 412(5–6):403–409

    Article  CAS  Google Scholar 

  24. Carmichael JD, Bonert VS, Mirocha JM, Melmed S (2009) The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 94(2):523–527

    Article  PubMed  CAS  Google Scholar 

  25. Kamenicky P, Dos Santos C, Espinosa C, Salenave S, Galland F, Le Bouc Y, Maison P, Bougnères P, Chanson P (2009) D3 GH receptor polymorphism is not associated with IGF1 levels in untreated acromegaly. Euro J Endocrinol 161(2):231–235

    Article  CAS  Google Scholar 

  26. Vierhapper H, Heinze G, Gessl A, Exner M, Bieglmayr C (2003) Use of the oral glucose tolerance test to define remission in acromegaly. Metabolism 52(2):181–185

    Article  PubMed  CAS  Google Scholar 

  27. Boero L, Manavela M, Danilowicz K, Alfieri A, Ballarino MC, Chervin A, Garcia-Basavilbaso N, Glerean M, Guitelman M, Loto MG, Nahmias JA, Rogozinski AS, Servidio M, Vitale NM, Katz D, Fainstein Day P, Stalldecker G, Mallea-Gil MS (2011) Comparison of two immunoassays in the determination of IGF-I levels and its correlation with oral glucose tolerance test (OGTT) and with clinical symptoms in acromegalic patients. Pituitary. doi:10.1007/s11102-011-0351-y

  28. Faje AT, Barkan AL (2010) Basal, but not pulsatile, growth hormone secretion determines the ambient circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab 95(5):2486–2491

    Article  PubMed  CAS  Google Scholar 

  29. Freda PU (2009) Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clin Endocrinol (Oxf) 71(2):166–170

    Article  CAS  Google Scholar 

  30. Minuto FM, Resmini E, Boschetti M, Rebora A, Fazzuoli L, Arvigo M, Giusti M, Ferone D (2011) Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience. Pituitary. doi:10.1007/s11102-011-0313-4

  31. Milani D, Carmichael JD, Welkowitz J, Ferris S, Reitz RE, Danoff A, Kleinberg DL (2004) Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development. J Clin Endocrinol Metab 89(5):2271–2274

    Article  PubMed  CAS  Google Scholar 

  32. Clemmons DR (2011) Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem 57(4):555–559

    Article  PubMed  CAS  Google Scholar 

  33. Arafat AM, Mohlig M, Weickert MO, Perschel FH, Purschwitz J, Spranger J, Strasburger CJ, Schofl C, Pfeiffer AF (2008) Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. J Clin Endocrinol Metab 93(4):1254–1262

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank Shirley McCartney, Ph.D., for assistance with manuscript preparation.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standards

This study was approved by the Oregon Health & Science University Institutional Review Board.

Author information

Authors and Affiliations

  1. Department of Medicine, Oregon Health & Science University, 3303 S.W. Bond Avenue, Portland, OR, 97239, USA

    Jessica A. Brzana, David Cook & Maria Fleseriu

  2. Department of Neurological Surgery, Oregon Health & Science University, Portland, OR, USA

    Chris G. Yedinak, Johnny B. Delashaw & Maria Fleseriu

  3. Department of Pathology, Oregon Health & Science University, Portland, OR, USA

    Hume S. Gultelkin

  4. Northwest Pituitary Center, Oregon Health & Science University, Portland, OR, USA

    Jessica A. Brzana, Chris G. Yedinak, Johnny B. Delashaw, Hume S. Gultelkin, David Cook & Maria Fleseriu

Authors
  1. Jessica A. Brzana
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chris G. Yedinak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Johnny B. Delashaw
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hume S. Gultelkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David Cook
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria Fleseriu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Fleseriu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brzana, J.A., Yedinak, C.G., Delashaw, J.B. et al. Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values?. Pituitary 15, 562–570 (2012). https://doi.org/10.1007/s11102-011-0369-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-011-0369-1

Keywords

Search

Navigation